tbuckley/cabot-search huggingface dataset:
Impact of Reduced Von Willebrand Factor-Cleaving Protease [ADAMTS13] In Pediatric Stroke: A Nested Case-Control Study
Authors: Ulrike Nowak-Gottl, Moritz Lambers, Sabine Thedieck, Daniela Manner, Rolf M. Mesters, Ralf Junker, Monika Stoll
Journal: Blood (2010)
Systemic Mastocytosis. A GIMEMA Multicenter Survey.
Authors: Livio Pagano, Caterina Giovanna Valentini, Pellegrino Musto, Morena Caira, Michela Rondoni, Maria Teresa Van Lint, Anna Candoni, Giovanni Martinelli, Simona Gatto, Chiara Cattaneo, Laura Marbello, Cecilia Caramatti, Carlo Castagnola, Enrico Maria Pogliani, Maria Enza Mitra, Fiorina Giona, Rossella Fanci, Luana Fianchi, Grazia Sanpaolo, Alessandro Pulsoni, Giuseppe Leone
Journal: Blood (2006)
TGF-β pathway activation primes naïve lymphocytes to support atopic phenotypes in humans
Authors: Jonathan Lyons, Yihui Liu, Chi A. Ma, Xiaomin Yu, Michael O'Connell, Jason Hughes, Joshua McElwee, Kelly D. Stone, Pamela A. Frischmeyer-Guerrerio, Steven M. Holland, Alexandra F. Freeman, Joshua D. Milner
Journal: Journal of Allergy and Clinical Immunology (2017)
Circulating Erythropoietin (EPO) and Pro-Inflammatory Markers in Elderly (&gt;/=65) Persons with and without Anemia.
Authors: Luigi Ferrucci, Jack M. Guralnik, Richard C. Woodman, Stefania Bandinelli, Fulvio Lauretani, Annamaria Corsi, Paulo H.M. Chaves, William B. Ershler, Dan L. Longo
Journal: Blood (2004)
IMST-21. GLIOBLASTOMA-DERIVED EXTRACELLULAR VESICLES DYNAMICALLY CARRY PDL1 AND SPECIFICALLY INHIBIT CD4+ AND CD8+ T-CELL ACTIVATION AND PROLIFERATION
Authors: Franz Ricklefs, Maria Carmela Speranza, Kyungheon Lee, Carmela Passaro, Hakho Lee, Ralph Weissleder, Agnieszka Bronisz, Sean E. Lawler, E. Antonio Chiocca
Journal: Neuro-Oncology (2016)
Prognostic factors of overall survival in head and neck cancer: Post-hoc exploratory results from the SPINNAKER trial—A phase III randomized clinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
Authors: S. Urba, J. Gatz, W. Shen, A. Hossain, K. Winfree, A. Koustenis, P. Peterson
Journal: Journal of Clinical Oncology (2011)

5531 Background: Recurrent and metastatic head and neck cancers (HNC) are generally incurable, with ~20% 1-year survival rate. The objective of this analysis was to examine the prognostic factors (clinical, demographic, and health-related quality of life) of overall survival (OS) in patients with recurrent or metastatic HNC. Methods: Five subscales and the Trial Outcome Index (TOI) summary score of the Functional Assessment of Cancer Therapy-Head and Neck Cancer (FACT-H&N) were used as quality-of-life measures; all of these had been modified to score from 0 to 100. Both univariate and multivariate Cox proportional hazards models were used to assess the effect of prognostic factors on OS. Results: Randomized patients were evaluable for this analysis if they had completed a baseline FACT-H&N assessment (n=704). Eastern Cooperative Oncology Group (ECOG) performance status (PS; 0/1 vs 2; HR=0.44, 95% CI: 0.35-0.56), prior surgery or radiotherapy in the last 6 months (yes vs no; HR=0.74, 95% CI: 0.61-0.90), oral cavity primary site (HR=1.37, 95% CI: 1.15-1.63), age <65 years (HR=0.74, 95% CI: 0.61-0.90), and being white (HR=1.21, 95% CI: 1.02-1.43) were significant predictors of OS in univariate models. Baseline scores on four FACT-H&N subscales (physical well-being, emotional well-being, functional well-being, and additional concerns-H&N) also significantly predicted OS in univariate models (HRs, 0.82-0.94; all p≤0.002), as did TOI (HR=0.78, 95% CI: 0.73-0.82; p<0.001). In the multivariate model, significant prognostic factors included ECOG PS; race; prior surgery/radiotherapy; age <65 years; and baseline scores of the FACT-H&N subscales of physical well-being, social/family well-being, and additional concerns-H&N (all p≤0.03). Median survival times by baseline TOI quartiles (lowest to highest) were 3.9, 6.2, 8.2, and 11.0 months (p<0.001). Conclusions: ECOG PS, age, prior surgery/radiotherapy in the last 6 months, oral cavity primary site, and the FACT-H&N subscales and TOI summary score are prognostic indicators of OS in recurrent and metastatic HNC.
Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases
Authors: Salvador Harguindey, Daniel Stanciu, Jesús Devesa, Khalid Alfarouk, Rosa Angela Cardone, Julian David Polo Orozco, Pablo Devesa, Cyril Rauch, Gorka Orive, Eduardo Anitua, Sébastien Roger, Stephan J. Reshkin
Journal: Seminars in Cancer Biology (2017)
An Adult with Enteritis and Hypogammaglobulinemia Found to Have Heterozygous STXBP2 Mutation
Authors: Kathleen Y. Wang, Kuan-Hsiang G. Huang, Patricia Takach, Olajumoke Fadugba, Andrea J. Apter, Judith Kelsen, Soma Jyonouchi, Kathleen E. Sullivan
Journal: Journal of Allergy and Clinical Immunology (2017)
Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC).
Authors: M. E. Trinkaus, R. J. Hicks, R. J. Young, L. J. Peters, B. J. Solomon, M. Bressel, J. Corry, R. Fisher, D. Binns, G. A. McArthur, D. Rischin
Journal: Journal of Clinical Oncology (2011)

5527 Background: Human papilloma virus associated oropharyngeal SCC (HPV +ve OPSCC) is a clinically and molecularly distinct disease from HPV-negative HNSCC, with a better prognosis. We sought to determine the relationship between hypoxia, a known adverse prognostic factor in patients with locally advanced HNSCC, and HPV status. Methods: Eligible patients had: stage III and IV HNSCC treated on phase I and II chemoradiation trials with 70 Gy combined with tirapazamine and cisplatin (TPZ/CIS) or cisplatin and 5FU (CIS/5FU); pretreatment hypoxic imaging using FMISO-PET; and known HPV status as determined by p16 immunohistochemistry. Separate analyses were also conducted to consider the impact of TPZ on HPVnegative tumors in the randomized TROG 98.02 trial. Hypoxia was assessed by qualitative scoring of FMISO uptake in both primary tumors and nodes as previously described (J Clin Oncol 24:2098-2104, 2006). Results: 63 patients were included in the analysis. Both p16 +ve OPSCC tumors and p16 -ve HNSCC tumors had a high prevalence of tumor hypoxia (74% and 80%). The distribution of hypoxia (primary, nodal) was also similar. In patients treated with CIS/5FU there was a trend for worse locoregional control in p16 negative (-ve) hypoxic tumors compared to non-hypoxic tumors, HR= 5.1; 95% CI, 0.62 – 42.38; p=0.145. In patients with p16 -ve hypoxic tumors treated on the randomized phase II trial, there was worse locoregional control on CIS/5FU compared to TPZ/CIS. (HR = 25; 95% CI, 3.01 – 208; p < 0.001) and worse failure-free survival (HR = 4.35, 95% CI, 1.71 – 11.24; p = 0.003). Only 1 out of 14 p16 +ve patients in either arm of the trial experienced locoregional failure. Conclusions: Hypoxia, as measured by FMISO-PET, is frequently present in both p16 +ve and -ve HNSCC. The presence of hypoxia in p16 -ve patients was predictive of better locoregional control and failure-free survival in patients treated with tirapazamine. Supported by a NHMRC project grant.
The Use of Laparoscopic Liver Biopsies in Pediatric Patients with Hepatic Dysfunction Following Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Sung Choi, Saleem Islam, Gregory Yanik, John E. Levine, Raymond J. Hutchinson, James L.M. Ferrara, Joel K. Greenson, Kenneth R. Cooke
Journal: Blood (2004)
Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.
Authors: William Blum, Sam Penza, Sherif Farag, Belinda Avalos, Guido Marcucci, Thomas Lin, John C. Byrd, Patrick Elder, Edward A. Copelan
Journal: Blood (2004)
Didox, a unique ribonucleotide reductase inhibitor and free radical scavenger, can protect against doxorubicin caused cardiotoxicity with enhanced antitumor activity
Authors: Howard L. Elford, Arturo J. Cardounel, Jay Zweier, Jon Henry, Ryan Sumpter, Oliver Oakley, Vincent Gallicchio
Journal: Cancer Research (2006)

2125  Doxorubicin (DOX) is the lead member of the class of anthracyclines having antitumor activity against hematological and solid cancers, and plays a prominent role in breast cancer therapy. Long term cardiomyopathy hinders clinical use of anthracyclines. The total dosage of Doxorubicin in treatment protocols is limited because of this concern. The prevailing thesis is that Doxorubicin injures the heart by generating damaging free radicals through iron-catalyzed redox cycling. Didox is a unique ribonucleotide reductase (RR) inhibitor possessing free radical scavenging and iron chelating properties while exhibiting anti-cancer activity on its own. Therefore Didox was tested to see if it could decrease DOX toxicity without reducing its anticancer activity. The cardioprotective effects of Didox were assessed, both acutely and chronically in the rat, using a Langendorff model of heart perfusion. Cardiac function, as measured by Rate Pressure Product (RPP), was decreased 40% by DOX alone, but was ameliorated with Didox infusion. Free radical presence, as measured by EPR spin trapping, showed that Didox treatment decreased the DOX-induced DMPO-OH signal intensity by greater than 80%. These results indicate that Didox offers cardioprotection against DOX mediated injury through its ability to scavenge free radicals. Chronic DOX toxicity studies were performed by weekly single dose i.v. injections of DOX or DOX + Didox. The progression of cardiomyopathy was monitored using echocardiography. After 8 weeks of treatment, DOX treated animals demonstrated marked cardiomyopathy as evidenced by fractional shortening. The animals were then sacrificed and the cardioprotective effects of Didox assessed by measuring functional and histological parameters. Chronic administration of DOX resulted in greater than 50% decrease in left ventricular function as measured by RPP, but Didox offered more than 40% restoration. Also, we examined the effect of Didox and the classical RR inhibitor, hydroxyurea, as well as Zinecard, the iron chelator used clinically, to protect against cardiotoxicity in the mammary (16/c) mouse tumor model singly and in combination with DOX. Both DOX and the RR inhibitors had antitumor activity when used alone producing a modest increase in survival over the untreated group. However, when DOX was combined with the RR inhibitors there was a significant (greater than additive) enhancement of the antitumor activity. These results further support our premise that a free radical scavenger can be used in conjunction with DOX and not impede its antitumor activity, and Didox may even enhance it. Therefore Didox has the potential to be a valuable addition to combination cancer treatment protocols that contain an anthracycline such as DOX.
Ovarian Cancer Drug Approved
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib
Authors: Jorge E. Cortes, Tim H. Brümmendorf, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Sashi Nadanaciva, Nathalie Bardy-Bouxin, Mark Shapiro, Eric Leip, Jeffrey H. Lipton, Carlo Gambacorti-Passerini
Journal: Blood (2015)
Single-Fraction Radiotherapy and Early Subjective Improvement in Pain
Authors: Charles R. Thomas
Journal: JAMA Oncology (2017)

Rachel McDonald, MD(C); Keyue Ding, PhD; Michael Brundage, MD, MSc; Ralph M. Meyer, MD; Abdenour Nabid, MD; Pierre Chabot, MD; Genevieve Coulombe, MD; Shahida Ahmed, MD; Joda Kuk, MD; A. Rashid Dar, MD; Aamer Mahmud, MD; Alysa Fairchild, MD; Carolyn F. Wilson, MSc; Jackson S. Y. Wu, MD, MSc; Kristopher Dennis, MD; Carlo DeAngelis, PharmD; Rebecca K. S. Wong, MBChB, MSc; Liting Zhu, MSc; Stephanie Chan, BSc(C); Edward Chow, MBBS, MSc, PhD, FRCPC
Autologous Cells Treat Knee Damage
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DDIS-19. OLAPARIB PENETRATES TUMOUR MARGINS AS WELL AS CONTRAST ENHANCING REGIONS OF GLIOBLASTOMA AT THERAPEUTIC LEVELS: INTERIM RESULTS OF THE OPARATIC TRIAL NCT01390571
Authors: Anthony Chalmers, Alan Jackson, Helen Swaisland, Colin Watts, Sarah Halford, Darren Hargrave, Alex McCormick
Journal: Neuro-Oncology (2016)

Drug delivery in glioblastoma (GBM) is challenging; poor activity may result from low biological efficacy and/or poor brain penetration. While the blood-brain barrier (BBB) is compromised in contrast-enhancing regions, little is known about BBB integrity and drug penetration in non-enhancing regions of GBM including tumour margins. Adverse clinical outcomes might reflect poor drug delivery to viable, invasive tumour cells in these regions. We evaluated tumour core and margin concentrations of olaparib (Lynparza), a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP). Preclinical studies indicate that >90% PARP inhibition is achieved at 10-100 nM olaparib. Pre-clinically, BBB penetration was assessed in MDCKII cells expressing MDR1 and by autoradiography of rats and mice treated with [14C]-olaparib. Clinically, seventeen patients with recurrent resectable GBM underwent tumour resection after four days of olaparib (tablet) dosing (100 – 400 mg daily). In three patients, additional biopsies were taken from tumour margin regions identified by 5-aminolaevulinic acid guided resection. Olaparib levels in snap frozen specimens were measured by LC-MS. Olaparib was a substrate for MDR1 and efflux was blocked by ketoconazole. Radioactivity was not detected in the central nervous systems of healthy rats or mice after single dose [14C]-olaparib, indicating no BBB penetration. Despite this, olaparib was detected in 49/50 tumour core specimens from 17 patients and 9/9 tumour margin specimens from 3 patients. Olaparib concentrations in tumour core specimens ranged from 138 to 1233 nM (mean 584 nM), similar to those observed in previous breast cancer studies. Tumour margin olaparib concentrations ranged from 308 to 1090 nM (mean 681 nM). Within individual patients, margin:core ratios ranged from 0.5 to 3.8 (mean 1.8). Olaparib is excluded from the CNS under normal conditions but reliably penetrates recurrent GBM at concentrations expected to effectively inhibit PARP. Preliminary results demonstrate similar penetration of tumour margins.
Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors
Authors: Andrew Spencer, Simon Harrison, Francis Burrows, Paul Mainwaring, Timothy Price, Michael J Millward, Peeter Padrik, Craig Underhill, Paul Cannell, Steven D Reich, Mohit Trikha
Journal: Blood (2015)
The role of oncologic health care providers in end of life discussions for women with recurrent gynecologic or breast cancer.
Authors: Ashley Stuckey, Katina Robison, Don S. Dizon, Michelle Rogers, Miles Ott, Susan Miller, Mary Politi, Melissa Clark
Journal: Journal of Clinical Oncology (2013)

e20543 Background: Advance care planning (ACP) is an important topic for women with metastatic or recurrent cancer. Unfortunately, data suggest ACP is often not discussed at health care visits. Because patients with metastatic or recurrent cancer are incurable, the issue of end of life (EOL) is one faced by patients and providers. This study evaluates how often oncologic health care providers initiate EOL conversations with their patients. Methods: Eligible patients included women with metastatic or recurrent gynecologic or breast cancer of ≥3 month’s duration in an academic women’s oncology program. Interviews were conducted by research staff. Clinical characteristics and documentation of EOL decisions were obtained through chart reviews. Data were analyzed using SAS v.9.3. Multivariate logistic regression was used to model the association of EOL discussions with ACP. The study was approved by the hospital and university Institutional Review Boards. Results: 200 women were enrolled; 64% had stage III-IV cancer at diagnosis. The majority was white (91%) with a mean age of 60 (range 35-82). A total of 638 providers were identified (mean: 3.2 providers per patient; 57% female). Health care provider type and gender were not associated with EOL discussions. Only 49 women (25%) recalled an EOL conversation with at least one provider which appeared to correspond to the low proportion of people with documented ACP. Only 42 (22%) had an advanced directive (AD) and 29 (15%) a health care proxy (HCP) in the chart. Having an EOL conversation with at least one provider was not associated with a chart-documented AD (OR=1.6, 95% CI=0.7-3.6) or HCP (OR=1.8, 95% CI=0.7-4.5). The time since recurrence was shorter for those reporting EOL conversations (1.7 vs. 3.1 years, p=.0274). Conclusions: In this study, oncologic health care providers infrequently initiated EOL discussions with their patients with metastatic or recurrent cancer. More concerning, patient recollection of an EOL discussion with a provider was not associated with chart-documented ACP. Further studies evaluating the factors limiting EOL discussions as well as studies testing interventions to improve provider documentation of the ACP are warranted.
RTHP-08. LONG-TERM FOLLOW UP OF HIGH-RISK LOW-GRADE GLIOMA PATIENTS TREATED WITH RADIOTHERAPY (RT) OR RT AND ADJUVANT TEMOZOLAMIDE OR PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) CHEMOTHERAPY AT A SINGLE INSTITUTION
Authors: Cole Kreofsky, Ryan Youland, Jan Buckner, Joon Uhm, Daniel Lachance, Nadia Laack
Journal: Neuro-Oncology (2016)

Long-term results of RTOG-9802 demonstrate a survival benefit for adjuvant radiotherapy (RT) with PCV (procarbazine, CCNU, and vincristine) chemotherapy compared to RT alone in high-risk low-grade gliomas (hrLGG). Moreover, RTOG-0424 yielded good survival for similar patients treated with RT and temozolamide (TMZ). We compared long-term survival outcomes of hrLGG patients eligible for RTOG-9802 who received RT or RT and adjuvant TMZ or PCV. Charts of 227 patients (≥18 years) with pathologically confirmed WHO grade II glioma (1997-2008) who met eligibility criteria for RTOG-9802 were retrospectively reviewed. Kaplan-Meier estimates were used to determine progression-free survival (PFS) and overall survival (OS) and compared using Log-rank test. Chemotherapy initiated within 6 months of RT was considered adjuvant. Median patient age was 42.2 years: 26% astrocytoma, 43% oligodendroglioma, and 31% mixed-oligoastrocytoma. Sixty-one patients (27%) received chemotherapy, of which, 41% and 59% received PCV and TMZ, respectively. TMZ was given to 14/15 (93%) astrocytomas, 8/24 (33%) oligodendrogliomas, and 14/22 (64%) mixed-oligoastrocytoma tumors. Median follow-up for surviving patients was 8.4 years (range: 0.2-18.1 years). Chemotherapy was associated with improved PFS and OS compared to RT alone (6.7 vs 4.1 years, p=0.02; and 15.2 vs 8.1, p=0.12, respectively). Median OS was 8.8 years for TMZ and 16.5 years for PCV (p=0.23). Chemotherapy was associated with significant OS ­improvement for astrocytomas (8.8 vs 5.0 years, p=0.04) and a non-significant OS improvement in oligodendrogliomas (16.4 vs 11.4 year, p=0.09). No improvement was seen in mixed-oligodastrocytomas. Similar to RTOG-9802, chemotherapy improved survival compared to RT in our small, retrospective study. TMZ was associated with improved survival in astrocytomas compared to RT alone. Though not statistically significant, PCV was associated with improved OS compared to TMZ, however, a higher proportion of oligodendroglioma patients received PCV. Molecular markers were not routinely assessed in this cohort during this era.
120P Survival outcomes of metastatic breast cancer who have been treated with bevacizumab and eribulin in the real world. - BEV + PTX followed by eribulin versus the reverse sequence
Authors: K. Matsui, M. Earashi, T. Nagata, A. Yoshikawa, W. Fukushima, Z. Nozaki, Y. Tanada, K. Oyama, K. Shimada, K. Kiyohara, T. Shimizu, K. Iwata, T. Yoshida, T. Ii, K. Maeda
Journal: Annals of Oncology (2016)
Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
Authors: T. Yoshino, J. Cleary, R. Mayer, K. Yoshida, L. Makris, F. Yamashita, A. Ohtsu, H.-J. Lenz, E. Van Cutsem
Journal: Annals of Oncology (2016)